---

Background&Objective: The papanicolaou (pap) smear has been used to screen women for cervical cancer since 1940. Unsatisfactory results induce anxiety in patients and doctors. Recently, a number of new technologies have been developed to improve the detection of cervical cancer. Increase the early detection of meaningful pap smear abnormalities, reduce the number of unsatisfactory smears and false negative results and provide fewer ambiguous results one of these method is the new test, include liquid-based to improve the quality and quantity of the cervical pap smear. The aim of this study is to evaluate rate of unsatisfactory smear of cervical cytology in two methods, conventional pap smear (CP) and liquid-Based (L.B).
Materials&Methods: A comparison cross – sectional study was performed from 2004-2005 on 1500 patients referred to the Ghaem hospital and private clinic. From all patients cervical cytology was taken randomly via two methods CP and L.B. Subsequently frequency unsatisfactory cervical cytology in tow methods evaluated. Statistical analysis using the SPSS soft ware was done and t-test and ?2 used for comparative evaluation.
Results: Considering the incidence of unsatisfactory cervical cytology in CP method %0.3 was and in LB method %1 was. Sensitivity of the C.P method was 68.8% and that of the L.B method was 83.1%.
Conclusion: In this study incidence unsatisfactory rate in L.B method was higher than C.P method.

---

Background and Objective: Due to high mortality and morbidity of the cervical cancer we decided to compare benefits and advers effects of Gemcitabine plus conventional chemoradiation with conventional chemoradiation with cisplatin alone in Imam Hossein hospital, in Tehran, Iran. Materials and Methods: This double blind clinical trial, was carried out on 34 patients with documented cervical carcinoma during 2006-07 the patients divided into two sub groups: (A)Conventional concurrent chemoradiation with cisplatin(N=18) versus(B) concurrent chemoradiation with cisplatin plus gemicitabine (N=16). The patients with clinical stage of IB2-IVA and normal cell blood count with normal renal and liver function tests included in the study. Irradiation was delivered to all patients through external and internal beams with same dose and schedule. The patients followed for 3 months at least. Clinical response rate and adverse events included Neutropenin, Thrombocytopenia, anemia, diarrhea, nausea, and vomiting compared in two groups with fisher exact test, and t-test. Results: Despite increasing of complete response rate with adding gemcitabine to conventional treatment(81.2% vs. 66.7%), the difference in two groups was not statistically significant. Conclusion: This study indicated that the addition of gemicatabine to conventional chemoradiation with cisplatinrevealed no significant benefits. All adverse events in combination chemotherapy group were greater than conventional treatment.